Studies
Expanded Access to the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Cancer
Pediatrics
Brain and Spinal Cord Cancer
Pediatric Subjects
Adult Subjects
Female Subjects
Male Subjects